Short answer
Prime Medicine, Inc. (PRME) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
Prime Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Business highlights included alongside financial results
- Full results and company commentary furnished in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss narrowed to $42.1M from $52.6M, while R&D fell to $33.4M from $41.4M
- Cash, investments, and restricted cash totaled $108.8M at June 30, 2026, with funding expected into 2027
- PM577a received U.S. IND and New Zealand CTA clearances, enabling global Phase 1/2 enrollment and 2027 data
- Beam arbitration affirmed Prime’s PM647 rights with no monetary damages; IND and/or CTA submission targeted for 3Q 2026
- PM359 received FDA RMAT designation, supporting regulatory discussions toward a potential BLA filing in 1H 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Prime Medicine, Inc. 8-K filings
Get the next PRME 8-K as it lands
Follow PRME for push alerts, or ask the research agent what this filing means.